A Significant Step Forward in Cancer Research Bold Therapeutics has officially announced a major achievement in its clinical development program: the company has reached the enrollment midpoint for its randomized Phase 2 clinical trial evaluating BOLD-100. This trial is specifically focused on patients battling second-line metastatic colorectal cancer (mCRC). Understanding the Potential of BOLD-100 BOLD-100…